Abstract
Background: Reversible cholinesterase inhibitors, when given prophylactically before exposure to organophosphates, are able to decrease organophosphate-induced mortality. However, the efficacy of pyridostigmine, the only pre-treatment substance approved by the US Federal Drug Administration, is unsatisfactory.
Methods: In search of a better prophylactic compound, we determined in vivo the protection conferred by five cholinesterase inhibitors (ranitidine, physostigmine, tacrine, K-27 and pyridostigmine), which were administered in equitoxic dosage (1/4 of LD01) 30 minutes before exposure to the organophosphate dicrotophos. Efficacy was measured in rats by Cox analysis calculating the relative risk of death (RR), RR being 1 for the reference group which received dicrotophos and no prophylaxis.
Results: K-27 (RR=0.06), physostigmine (RR=0.15), pyridostigmine (RR=0.22) and tacrine (RR=0.28) significantly (p ≤ 0.05) reduced dicrotophos-induced mortality in comparison to the reference group (dicrotophos without pre-treatment), whereas ranitidine (RR=0.86) had no significant influence. The experimental oxime K-27, when given before dicrotophos exposure, conferred the best in vivo protection. This was significantly (p ≤ 0.05) more efficacious than pre-treatment with any other tested compound. The differences in efficacy between the second best compound, physostigmine, and the less efficacious substances (tacrine and pyridostigmine) were also statistically significant.
Conclusion: These data indicate that K-27 can be considered a very efficacious prophylactic agent for organophosphate exposure.
Keywords: Carbamates, cholinesterase, cox analysis, dicrotophos, organophosphate, prophylaxis, rat.
Current Pharmaceutical Design
Title:Optimal Pre-treatment for Acute Exposure to the Organophosphate Dicrotophos
Volume: 23 Issue: 23
Author(s): Dietrich E. Lorke*, Syed M. Nurulain, Mohamed Y. Hasan, Kamil Kuca and Georg A. Petroianu
Affiliation:
- Department of Cellular Biology & Pharmacology, Herbert Wertheim College of Medicine, Florida International University, University Park GL 495 D, 11200 SW 8th St, Miami 33199, Florida,United States
Keywords: Carbamates, cholinesterase, cox analysis, dicrotophos, organophosphate, prophylaxis, rat.
Abstract: Background: Reversible cholinesterase inhibitors, when given prophylactically before exposure to organophosphates, are able to decrease organophosphate-induced mortality. However, the efficacy of pyridostigmine, the only pre-treatment substance approved by the US Federal Drug Administration, is unsatisfactory.
Methods: In search of a better prophylactic compound, we determined in vivo the protection conferred by five cholinesterase inhibitors (ranitidine, physostigmine, tacrine, K-27 and pyridostigmine), which were administered in equitoxic dosage (1/4 of LD01) 30 minutes before exposure to the organophosphate dicrotophos. Efficacy was measured in rats by Cox analysis calculating the relative risk of death (RR), RR being 1 for the reference group which received dicrotophos and no prophylaxis.
Results: K-27 (RR=0.06), physostigmine (RR=0.15), pyridostigmine (RR=0.22) and tacrine (RR=0.28) significantly (p ≤ 0.05) reduced dicrotophos-induced mortality in comparison to the reference group (dicrotophos without pre-treatment), whereas ranitidine (RR=0.86) had no significant influence. The experimental oxime K-27, when given before dicrotophos exposure, conferred the best in vivo protection. This was significantly (p ≤ 0.05) more efficacious than pre-treatment with any other tested compound. The differences in efficacy between the second best compound, physostigmine, and the less efficacious substances (tacrine and pyridostigmine) were also statistically significant.
Conclusion: These data indicate that K-27 can be considered a very efficacious prophylactic agent for organophosphate exposure.
Export Options
About this article
Cite this article as:
Lorke E. Dietrich*, Nurulain M. Syed, Hasan Y. Mohamed, Kuca Kamil and Petroianu A. Georg, Optimal Pre-treatment for Acute Exposure to the Organophosphate Dicrotophos, Current Pharmaceutical Design 2017; 23 (23) . https://dx.doi.org/10.2174/1381612822666161027154303
DOI https://dx.doi.org/10.2174/1381612822666161027154303 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Subset Selection and Docking of Human P2X7 Inhibitors
Current Computer-Aided Drug Design The Role of Food Addiction in Clinical Research
Current Pharmaceutical Design Critical Atomic-level Processing Technologies: Remote Plasma-enhanced Atomic Layer Deposition and Atomic Layer Etching
Micro and Nanosystems Human T-Cell Lymphotropic Virus in Patients Infected with HIV-1: Molecular Epidemiology and Risk Factors for Transmission in Piaui, Northeastern Brazil
Current HIV Research Computational Analysis of TRAPPC9: Candidate Gene for Autosomal Recessive Non-Syndromic Mental Retardation
CNS & Neurological Disorders - Drug Targets Thymidylate Kinase: An Old Topic Brings New Perspectives
Current Medicinal Chemistry Physiological and Non-Redundant Functions of PKC Isotypes in T Lymphocytes
Current Immunology Reviews (Discontinued) Oncogenic LncRNA CASC9 in Cancer Progression
Current Pharmaceutical Design Animal Models of Depressive Illness: The Importance of Chronic Drug Treatment
Current Pharmaceutical Design From Proteomic Studies to Molecular Pathways - Proteins Involved in Response to Methamphetamine Administration
Current Proteomics Quantitative Electroencephalogram Analysis in Parkinson’s Disease
Neuroscience and Biomedical Engineering (Discontinued) Genetic Association Analysis of NOS1 and Methamphetamine-Induced Psychosis Among Japanese
Current Neuropharmacology The Pivotal Role of Multimodality Reporter Sensors in Drug Discovery: From Cell based Assays to Real Time Molecular Imaging
Current Pharmaceutical Biotechnology Apo-E4 Allele in Conjunction with Aβ42 and Tau in CSF: Biomarker for Alzheimers Disease
Current Alzheimer Research Cell Signaling Mechanisms by which Geniposide Regulates Insulin- Degrading Enzyme Expression in Primary Cortical Neurons
CNS & Neurological Disorders - Drug Targets Diversified Synthetic Pathway of 1, 4-Dihydropyridines: A Class of Pharmacologically Important Molecules
Mini-Reviews in Medicinal Chemistry Phytocannabinoids: General Aspects and Pharmacological Potential in Neurodegenerative Diseases
Current Neuropharmacology Immune and Metabolic Interactions of Human Erythrocytes: A Molecular Perspective
Endocrine, Metabolic & Immune Disorders - Drug Targets Angiogenesis Inhibition in the Treatment of Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Peptides As Therapeutics with Enhanced Bioactivity
Current Medicinal Chemistry